

ABOUT THE K36-MMSET-001 STUDY

▶ BACKGROUND

The K36-MMSET-001 study has been designed to assess the effectiveness and safety of KTX-1001, an investigational* drug for patients with T(4;14) multiple myeloma. **KTX-1001 (gintemeostat) will be combined with standard of care therapies, as well as mezigdomide, an investigational drug that blocks a protein overexpressed in multiple myeloma.**

*"Investigational" means the study drug is available for use in clinical research but not yet available for the treatment of Multiple Myeloma.

♥ ELIGIBILITY

- ✓ At least 18 years of age
- ✓ Have confirmed diagnosis of T(4;14) relapsed or refractory multiple myeloma
- ✓ Received at least 1~2 prior treatments for your multiple myeloma. Mezi cohort only ≥ 2

🎯 STUDY DESIGN

The K36-MMSET-001 study includes KTX-1001 and standard of care therapies and investigational therapies. You will be assigned to one of the following combinations:

COMBINATION GROUPS:

Participants will receive KTX-1001 (gintemeostat) in two different doses (Dose #1 & Dose #2) determined combined with standard-of-care medications.

KTX-1001 (D1 & D2) Carfilzomib + DEX
KTX-1001 (D1 & D2) Pomalidomide + DEX
KTX-1001 (D1 & D2) Mezigdomide + DEX

CONTACT US



1 MAIN STREET, 13FL, CAMBRIDGE, MA 02142



WWW.K36TX.COM



INFO@K36TX.COM



WWW.LINKEDIN.COM/COMPANY/K36-THERAPEUTICS



WWW.INSTAGRAM.COM/K36TX



WWW.TWITTER.COM/K36TX



WWW.FACEBOOK.COM/K36TX

DO YOU OR YOUR LOVED ONE HAVE T(4;14) MULTIPLE MYELOMA?



We have a clinical trial for patients who are looking for potential new treatment options. If you have relapsed or refractory multiple myeloma you may want to consider participating in the K36-MMSET-001 study.



k36
therapeutics

PARTICIPATING IN THE STUDY

▶ WHAT ARE CLINICAL STUDIES?

Without clinical studies and the volunteers who participate in these studies no potential new treatments could be developed. Clinical studies:

- **Find new ways** to prevent, detect or treat conditions, including multiple myeloma.
- **Provide important information** about the safety and effectiveness of potential new medications.
- **Follow standards and are closely regulated.** Every study is reviewed and monitored carefully to make sure that the rights of participants are protected, no unnecessary risks are involved and that the study answers important medical questions.

▶ THE GOAL OF PHASE I STUDIES IS TO FIND OUT:

Phase I clinical studies include a small number of participants with the condition under study.

- ✓ How well the study drug works
- ✓ Potential side effects of the study drug
- ✓ A tolerable dose for the study drug
- ✓ If the study drug will work for your condition

▶ WHAT WILL HAPPEN IF I PARTICIPATE?

If you are interested in the study, you will:

- **Be given an informed consent form** to read and sign. This form will provide you with all study details, including potential risks and benefits, and you will be given a chance to ask any questions you might have before signing the consent form.
- **Complete the screening period** where study doctors will ask you a number of medical questions and you will have health tests performed to determine if you qualify for this study.

If during the study you change your mind, you are free to leave at any point. During the study, the study drug will be provided to you at no charge.

▶ WHAT HAPPENS AT STUDY VISITS?

At the study visits, you will:

- **Have health checks** including, temperature, blood pressure, pulse, and breathing rate, blood/urine tests, bone marrow samples, and imaging to assess your disease.
- **Talk with your study doctor or study team** and they will answer questions you may have.
- **Receive the study drug**, based on part of the study and dose level that your study doctor will provide.
- **Be given a study diary** and instructions on how to complete the diary.
- **Take KTX-1001 by mouth and other medications as instructed.**



Screening Period

Up to 28 Days

Informed consent followed by screening tests and procedures to find out if you qualify to participate in the study

Participant qualifies for the study

Treatment Period

4-week Treatment Cycles

After first 2 months (2 cycles), study visits are monthly

End of Treatment Visit
(if your disease becomes worse or adverse events that is not tolerable)

Post Treatment Visit

Myeloma Follow up